Hogan Lovells advises Marinus Pharmaceuticals in sale to Immedica Pharma

Hogan Lovells advises Marinus Pharmaceuticals in sale to Immedica Pharma

Press releases | 17 February 2025

Philadelphia, Washington, D.C. 17 February 2025 – Global law firm Hogan Lovells advised Marinus Pharmaceuticals, Inc. (Marinus) (Nasdaq: MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, in its sale to Immedica Pharma AB (Immedica), a leading global rare disease company.

Immedica, based in Stockholm, announced the completion of the acquisition of Marinus through its indirect wholly owned subsidiary Matador Subsidiary, Inc., a Delaware corporation.

As a result of the transaction, Marinus has become an indirect wholly owned subsidiary of Immedica, and the common stock of Marinus will cease to be traded on the Nasdaq Global Market.

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. Marinus’ product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the United States in 2022.

The Hogan Lovells team was led by partners Jessica Bisignano (M&A, Philadelphia) and Gabrielle Witt (M&A, Washington, D.C.) with support from partners Les Reese (Capital Markets, Washington, D.C.) and Allison Wuertz (Litigation, New York), and senior associates Gibby Wagner (M&A, Philadelphia) and Gil McDonald (Capital Markets, Washington D.C.). Partners Steve Abrams and Stephen Nicolai (both Capital Markets, Philadelphia), and senior associate Amanda Brown (Capital Markets, Philadelphia) served as Securities and Governance counsel to Marinus until its sale.